30
Participants
Start Date
June 30, 2024
Primary Completion Date
April 30, 2027
Study Completion Date
July 31, 2027
Hetrombopag
Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.
RECRUITING
Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University, Beijing
Beijing Children's Hospital
OTHER